// App-Quantinova.ai

1592 : Impact of Comorbidities and Comedications on the Effectiveness of Ombitasvir/Parita‐ previr/Ritonavir ± Dasabuvir ± Ribavirin in Clinical Practice: Real‐World Evidence From a Multicountry Postmarketing Observational Study

Researchers

Presenter

  • Stefan Bourgeois

Principal Investigators

  • Manuela G. Curescu

  • Dominique G. Larrey

  • Fiona Marra

  • Patrick Dorr

  • Mariem Charafeddine

  • Eric Crown

  • Mark Bondin

  • David J. Back

Medical Centers

  • Department of Gastroenterology and Hepatology, Zna Antwerp, Belgium

  • Clinic of Infectious Diseases, University of Medicine and Pharmacy Timisoara, Timisoara, Romania

  • Hepato-Gastroenterologie B, Hopital St Eloi, Montpellier, France

  • Department of Cellular and Molecular Physiology, University of Liverpool, Liverpool, United Kingdom

  • AbbVie, Inc., North Chicago, IL

Locations

  • Belgium

  • Romania

  • France

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Cirrhosis

Biomarkers

  • N/A

Drug/Treatment

  • ombitasvir

  • Interferon

  • Exviera

  • Ritonavir

  • Ribavirin

Outcome

  • N/A

Study Design

  • Observational

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved